Venetoclax, the sole globally approved Bcl-2 selective inhibitor, has received approval for the treatment of relapsed or refractory chronic lymphocytic leukemia and acute myeloid leukemia in elderly patients. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.